» Articles » PMID: 24148923

Manganism in the 21st Century: the Hanninen Lecture

Overview
Journal Neurotoxicology
Date 2013 Oct 24
PMID 24148923
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Since the original description of the health effects of inhaled occupational manganese (Mn) by Couper in 1837, an extensive literature details the clinical syndrome and pathophysiology of what was thought to be a rare condition. In the last decade, conventional wisdom regarding the clinicopathological effects of Mn has been challenged. Past exposures to Mn were an order of magnitude higher than modern exposures in developed countries; therefore, the clinical syndrome seen in the time of Couper is no longer typical of modern Mn exposed workers. Parkinsonism (rigidity, bradykinesia, rest tremor, and postural instability) is present in 15% of Mn-exposed workers in welding industries, and these parkinsonian signs are associated with reduced health status and quality of life. These parkinsonian signs also overlap considerably with the clinical findings seen in early stages of Parkinson's disease (PD); although, molecular imaging suggests that Mn-exposed workers have dopaminergic dysfunction in a pattern unique from PD. Furthermore, geographic information system studies demonstrate that regions of the US with high industrial Mn emissions have an increased incidence of PD and increased PD associated mortality. This review will contrast historical, descriptive human studies in Mn-exposed subjects with more recent data and will suggest a research agenda for the 21st century.

Citing Articles

Targets to Search for New Pharmacological Treatment in Idiopathic Parkinson's Disease According to the Single-Neuron Degeneration Model.

Huenchuguala S, Segura-Aguilar J Biomolecules. 2024; 14(6).

PMID: 38927076 PMC: 11201619. DOI: 10.3390/biom14060673.


Magnetic Resonance Imaging and Manganism: A Narrative Review and Laboratory Recommendations.

Majewski M, Piwko K, Ordak M, Muszynska E, Nasierowski T, Bujalska-Zadrozny M J Clin Med. 2024; 13(10).

PMID: 38792364 PMC: 11122624. DOI: 10.3390/jcm13102823.


Diagnosis of manganism and manganese neurotoxicity: A workshop report.

Mattison D, Momoli F, Alyanak C, Aschner M, Baker M, Cashman N Med Int (Lond). 2024; 4(2):11.

PMID: 38410758 PMC: 10895461. DOI: 10.3892/mi.2024.135.


as a suitable model to evaluate the toxicity of water from Rolante River, southern Brazil.

Rodrigues V, Menezes J, da Silva L, Muller I, Mallmann L, Hermann B Toxicol Res (Camb). 2024; 13(1):tfad117.

PMID: 38178995 PMC: 10762661. DOI: 10.1093/toxres/tfad117.


Common and Trace Metals in Alzheimer's and Parkinson's Diseases.

Doroszkiewicz J, Farhan J, Mroczko J, Winkel I, Perkowski M, Mroczko B Int J Mol Sci. 2023; 24(21).

PMID: 37958705 PMC: 10649239. DOI: 10.3390/ijms242115721.


References
1.
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A . Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004; 351(24):2498-508. DOI: 10.1056/NEJMoa033447. View

2.
Koller W, Lyons K, Truly W . Effect of levodopa treatment for parkinsonism in welders: A double-blind study. Neurology. 2004; 62(5):730-3. DOI: 10.1212/01.wnl.0000113726.34734.15. View

3.
Wright Willis A, Evanoff B, Lian M, Criswell S, Racette B . Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology. 2010; 34(3):143-51. PMC: 2865395. DOI: 10.1159/000275491. View

4.
Schoenberg B, Anderson D, HAERER A . Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology. 1985; 35(6):841-5. DOI: 10.1212/wnl.35.6.841. View

5.
Hauser R, Zesiewicz T, Martinez C, Rosemurgy A, Olanow C . Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease. Can J Neurol Sci. 1996; 23(2):95-8. DOI: 10.1017/s0317167100038786. View